Becton, Dickinson and Company (BDX)

In the past six months, Becton, Dickinson & Co. experienced a stock price decrease of over 10% on May 2, 2025. The company declared dividends of $1.0400 per share on April 29, 2025, and again on July 22, 2025. On October 15, 2025, BD announced a CFO transition plan. An update on a clinical study for the BD Prevue™ II Peripheral Vascular Access System was submitted on September 19, 2025, and announced on October 27, 2025. Shares of various medical technology companies, including BDX, saw a slight decline around September 25, 2025, due to a U.S. Commerce Department investigation. BD is scheduled to announce its financial results for the fourth quarter and full fiscal year 2025 on November 6, 2025. As of October 26, 2025, the company's overall moving average trend leaned bearish, and analysts currently have a consensus "Hold" rating on the stock.

Demand for Becton, Dickinson & Co.'s products and services is generally stable and less subject to significant seasonality due to the essential nature of healthcare needs. The company has experienced strong sales in drug-delivery devices, fueled by increased demand and a rise in elective surgeries. The pharmaceutical business, especially demand for injectables like GLP-1s, is expected to continue its robust growth. While the Bioscience sector has faced some challenges, the overall demand for medical devices and diagnostic products tends to be consistent.

Becton, Dickinson & Co. (BDX) is a global medical technology company focused on developing, manufacturing, and selling medical supplies, devices, laboratory equipment, and diagnostic products. The company operates in the Healthcare sector, specifically in the Medical Instruments & Supplies industry. BD's business is structured around three primary segments: BD Medical, which focuses on medication delivery and management; BD Life Sciences, dedicated to advancing diagnostics and research; and BD Interventional, which concentrates on minimally invasive surgical and interventional procedures.

Becton, Dickinson & Co. has a significant global presence, operating in over 190 countries and employing over 75,000 people worldwide. The company markets its products across the Americas, Europe, the Middle East, Africa, and Asia-Pacific. International markets accounted for more than 50% of the company's total revenues in 2015, with emerging markets being a key driver of sales. BD also maintains manufacturing facilities in numerous countries.

In the past year, Becton, Dickinson & Co. has maintained a generally positive brand reputation. BD celebrated 55 years of manufacturing excellence at its Sumter, South Carolina facility on October 3, 2025. The company announced the launch of new AI-enabled solutions on October 20, 2025, and introduced a new self-collection solution for HPV testing in markets outside the United States on October 22, 2025. Forbes recognized BD in several lists for 2025. However, an "Update on Alert: Infusion Set Performance Issue from BD" was reported by the FDA on September 29, 2025, which could potentially affect the company's reputation.

Becton, Dickinson & Co. is primarily owned by institutional investors, who hold approximately 87% to 90.22% of the company's stock. Insiders own a smaller portion, ranging from 0.14% to 0.66%, while retail investors hold about 9.12% to 12% of the shares. Major institutional shareholders include Vanguard Group Inc., BlackRock, Inc., T. Rowe Price Investment Management Inc., State Street Corp., First Eagle Investment Management LLC, Massachusetts Financial Services Co., and Geode Capital Management LLC. There has been some insider selling activity in the past quarter.